Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
Saved in:
| Title: | Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. |
|---|---|
| Authors: | Elsaid MI; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Li N; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Firkins SA; Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA., Rustgi VK; Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.; Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA., Paskett ED; Division of Population Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Acharya C; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Reddy KR; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Chiang CW; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Mumtaz K; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 May; Vol. 59 (9), pp. 1096-1110. Date of Electronic Publication: 2024 Mar 27. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38538967 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Elsaid+MI%22">Elsaid MI</searchLink>; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Li+N%22">Li N</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Firkins+SA%22">Firkins SA</searchLink>; Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Rustgi+VK%22">Rustgi VK</searchLink>; Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.; Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Paskett+ED%22">Paskett ED</searchLink>; Division of Population Sciences, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.; Department of Internal Medicine, Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Acharya+C%22">Acharya C</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Reddy+KR%22">Reddy KR</searchLink>; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Chiang+CW%22">Chiang CW</searchLink>; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Mumtaz+K%22">Mumtaz K</searchLink>; Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, Ohio, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228707234%22">Alimentary pharmacology & therapeutics</searchLink> [Aliment Pharmacol Ther] 2024 May; Vol. 59 (9), pp. 1096-1110. <i>Date of Electronic Publication: </i>2024 Mar 27. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8707234 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2036 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202692813%22">02692813 </searchLink><i>NLM ISO Abbreviation: </i>Aliment Pharmacol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38538967 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/apt.17925 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1096 Titles: – TitleFull: Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Elsaid MI – PersonEntity: Name: NameFull: Li N – PersonEntity: Name: NameFull: Firkins SA – PersonEntity: Name: NameFull: Rustgi VK – PersonEntity: Name: NameFull: Paskett ED – PersonEntity: Name: NameFull: Acharya C – PersonEntity: Name: NameFull: Reddy KR – PersonEntity: Name: NameFull: Chiang CW – PersonEntity: Name: NameFull: Mumtaz K IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2024 May Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1365-2036 Numbering: – Type: volume Value: 59 – Type: issue Value: 9 Titles: – TitleFull: Alimentary pharmacology & therapeutics Type: main |
| ResultId | 1 |